FDA 483 - Chemisphere Corporation - March 17, 2020
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Chemisphere Corporation, a pharmaceutical manufacturer in Saint Louis, Missouri, revealed significant deficiencies. Observations included a lack of appropriate controls over computer systems, allowing unauthorized changes and hindering audit trail review, as well as the use of undocumented "Post-It Notes" as raw data. Additionally, the firm's complaint records were found to be deficient, lacking documentation for decisions not to conduct required investigations.
ID · ee024196-3a5f-4880-afb8-ad2b96f87d1f